Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8+ T cell responses in mice

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 3, 2014, Pages 571-578

  Zhou, Weibin ^a   Moguche, Albanus O ^b   Chiu, David ^a,c   Murali Krishna, Kaja ^b,d   Baneyx, François ^a,c  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Washington   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomineralization; Nanocarrier; Nanovaccine; Solid binding peptide

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; BIOMINERALIZATION; CALCIUM PHOSPHATE; CELLS; CYTOLOGY; DEVELOPING COUNTRIES; MAMMALS; NANOPARTICLES; PEPTIDES; VACCINES; VIRUSES;

INFECTIOUS DISEASE; JUST-IN-TIME MANUFACTURING; NANOCARRIERS; NANOVACCINE; PHOSPHATE BINDING; SHELL NANOPARTICLES; SOLID-BINDING PEPTIDES; VACCINE PRODUCTION;

T-CELLS;

CALCIUM PHOSPHATE; GAMMA INTERFERON; HYBRID PROTEIN; NANOPARTICLE; OVALBUMIN; TRXA PA44 OVA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BIOMINERALIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HYDRODYNAMICS; IMMUNOGENICITY; INFLUENZA VIRUS; ION EXCHANGE CHROMATOGRAPHY; LIGHT SCATTERING; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; VACCINATION; VACCINE PRODUCTION;

MUS; ORTHOMYXOVIRIDAE;

BIOMINERALIZATION; NANOCARRIER; NANOVACCINE; SOLID BINDING PEPTIDE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CALCIUM PHOSPHATES; CD8-POSITIVE T-LYMPHOCYTES; CHICKENS; FEMALE; HUMANS; MICE; NANOPARTICLES; OVALBUMIN; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES;

EID: 84896547663     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.11.007     Document Type: Article

References (42)

1. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
2. Correia-Pinto J.F., Csaba N., Alonso M.J. Vaccine delivery carriers: insights and future perspectives. Int J Pharm 2013, 440:27-38.
3. Joshi M.D., Unger W.J., Storm G., van Kooyk Y., Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 2012, 161:25-37.
4. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 20:68-89.
5. Swartz M.A. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001, 50:3-20.
6. Bachmann M.F., T.J.J. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
7. Salerno-Gonçalves R., Sztein M.B. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol 2006, 14:536-542.
8. Yewdell J.W. Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol 2010, 22:402-410.
9. Amorij J.-P., Kersten G.F.A., Saluja V., Tonnis W.F., Hinrichs W.L.J., Slütter B., et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release 2012, 161:363-376.
10. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
11. Sarikaya M., Tamerler C., Jen A.K., Schulten K., Baneyx F. Molecular biomimetics: nanotechnology through biology. Nat Mater 2003, 2:577-585.
12. Sarikaya M., Tamerler C., Schwartz D.T., Baneyx F. Materials assembly and formation using engineered polypeptides. Annu Rev Mater Res. 2004, 34:373-408.
13. Dickerson M.B., Sandhage K.H., Naik R.R. Protein- and peptide directed synthesis of inorganic materials. Chem Rev 2008, 108:4935-4978.
14. Briggs B.D., Knecht M.R. Nanotechnology meets biology: peptide-based methods for the fabrication of functional materials. J Phys Chem Lett. 2012, 3:405-418.
15. Coyle B.L., Zhou W., Baneyx F. Protein-aided mineralization of inorganic nanostructures. Bionanotechnology: biological self-assembly and its applications 2013, Caister Academic Press, Norwich, U.K. B.H.A. Rehm (Ed.).
16. Zhou W., Schwartz D.T., Baneyx F. Single pot biofabrication of zinc sulfide immuno-quantum dots. J Am Chem Soc 2010, 132:4731-4738.
17. Zhou W., Baneyx F. Aqueous, protein-driven synthesis of transition metal-doped ZnS immuno-quantum dots. ACS Nano 2011, 5:8013-8018.
18. Chiu D., Zhou W., Kitayaporn S., Schwartz D.T., Murali-Krishna K., Kavanagh T.J., et al. Biomineralization and size control of calcium phosphate core-protein shell nanoparticles: potential for vaccine applications. Bioconjug Chem 2012, 23:610-617.
19. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble proteins into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
20. Kopper R.A., Stallcup T., Hufford G., Liakaros C.D. The 5'-end structure of ovalbumin mRNA in isolated nuclei and polysomes. Nucleic Acids Res 1994, 22:4504-4509.
21. + T cells to the lung during influenza pneumonia. J Immunol 2001, 167:6983-6990.
22. b-/- mice, but provide minimal protection. J Immunol 2003, 170:1987-1994.
23. Peled J.U., Kuang F.L., Iglesias-Ussel M.D., Roa S., Kalis S.L., Goodman M.F., et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008, 26:481-511.
24. Stavnezer J., Guikema J.E.J., Schrader C.E. Mechanism and regulation of class switch recombination. Annu Rev Immunol 2008, 26:261-292.
25. MacLennan I.C.M., Gulbranson-Judge A., Toellner K.M., Casamayor-Palleja M., Chan E., Sze D.M.Y., et al. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev 1997, 156:53-66.
26. MacLeod M.K.L., David A., McKee A.S., Crawford F., Kappler J.W., Marrack P. Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J Immunol 2011, 186:2889-2896.
27. Flynn K.J., Belz G.T., Altman J.D., Ahmed R., Woodland D.L., Doherty P.C. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998, 8:683-691.
28. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
29. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
30. Manalova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachman M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
31. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173:3148-3154.
32. Pfeifer J.D., Wick M.J., Roberts R.L., Findlay K., Normark S.J., Harding C.V. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993, 361:359-362.
33. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994, 153:4925-4933.
34. Sun L., Chow L.C., Frukhtbeyn S.A., Bonevich J.E. Preparation and properties of nanoparticles of calcium phosphate with various Ca/P ratios. J Res Natl Inst Stand Technol. 2010, 115:243-255.
35. Tran K.K., Shen H. The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials 2009, 30:1356-1362.
36. Howland S.W., Wittrup K.D. Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol 2008, 180:1576-1583.
37. He Q., Mitchell A.R., Johnson S.L., Wagner-Bartak C., Morcol T., Bell S.J.D. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 2000, 7:899-903.
38. He Q., Mitchell A., Morcol T., Bell S.J.D. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 2002, 9:1021-1024.
39. Tritto E., Mosca F., Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27:3331-3334.
40. Rudra J.S., Tian Y.F., Jung J.P., Collier J.H. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A 2010, 107:622-627.
41. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007, 27:363-371.
42. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009, 28:195-204.